Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27158527 | 1.00 | FUCA1 (0.55) | FUCA1SIGMAR1S1PR1S1PR5GBA1 | |
| Trifluoroacetic Acid SCHEMBL29977328 | 0.86 | S1PR5 (0.48) | FUCA1SIGMAR1S1PR1S1PR5GBA1 | |
| SCHEMBL9052958 | 0.80 | FUCA1 (0.58) | FUCA1SIGMAR1S1PR1S1PR5GBA1 | |
| SCHEMBL14410730 | 0.78 | FUCA1 (0.56) | FUCA1SIGMAR1S1PR1S1PR5GBA1 | |
| SCHEMBL402305 | 0.78 | FUCA1 (0.56) | FUCA1SIGMAR1S1PR1S1PR5GBA1 | |
| SCHEMBL3931239 | 0.78 | FUCA1 (0.56) | FUCA1SIGMAR1S1PR1S1PR5GBA1 | |
| SCHEMBL16759827 | 0.77 | FUCA1 (0.64) | FUCA1SIGMAR1S1PR1S1PR5GBA1 | |
| SCHEMBL16775256 | 0.77 | FUCA1 (0.64) | FUCA1SIGMAR1S1PR1S1PR5GBA1 | |
| SCHEMBL5242542 | 0.77 | FUCA1 (0.64) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL3522692 | 0.77 | FUCA1 (0.55) | FUCA1SIGMAR1S1PR1S1PR5GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| EP-4322954-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | FUCA1 4054/4885SIGMAR1 4769/4885S1PR1 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.